Updated:
Odan Laboratories Ltd
Odan Laboratories Ltd is a Canadian specialty pharmaceutical company founded in 1974, vertically integrated for R&D, manufacturing, and distribution.
Odan Laboratories Ltd
Odan Laboratories Ltd was founded in 1974 in Montreal, Canada, and remains a wholly Canadian-owned specialty pharmaceutical company. Its initial product portfolio concentrated on generic pharmaceuticals, and it has since expanded into specialty areas including gastroenterology, dermatology, and hospital-based therapeutics. The company operates with full vertical integration — handling R&D, manufacturing, distribution, and marketing in-house. Its product line includes Anodan-HC, Proctodan-HC, Proctol, Lidodan, Prochlorperazine Suppositories, and Indomethacin Suppositories. Odan distributes to retail pharmacies, hospitals, government institutions, clinics, and wholesalers across Canada, and exports to several international markets. The firm also actively acquires complementary businesses, as demonstrated by its acquisition of Ilkos Therapeutic Inc. (per the firm's website, 2026). Odan does not publicly disclose financial metrics such as AUM or annual revenue, nor the identities of its principals or ownership structure. It maintains a lean public profile, with no listed LinkedIn presence or known professional team count. The acquisition of Ilkos Therapeutic Inc. is the most recent publicly dated operational event. Odan's structural differentiator lies in its complete vertical integration within a single ownership structure — rare among small-to-mid-sized pharmaceutical firms. It handles everything from molecule development to final distribution without outsourcing R&D or manufacturing, and it pursues targeted acquisitions to bolster its portfolio and market reach.
General information
Firm type
Single Family Office
Year founded
1974
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Pointe-Claire
Corporate office
Pointe-Claire, QC, Canada
Sector focus
Frequently asked questions
Who controls Odan Laboratories Ltd?
Odan Laboratories Ltd does not publicly disclose its ownership or principal leadership structure. No named executives, board members, or family beneficiaries appear on its website or in public records. The company operates as a private Canadian entity (per the firm's website).
What is Odan's business model?
Odan is a fully integrated specialty pharmaceutical company — it researches, develops, manufactures, markets, and distributes its own products. It targets generic and specialty pharmaceuticals, with a focus on gastroenterology, dermatology, and hospital products. Distribution reaches retail pharmacies, hospitals, government institutions, and wholesalers in Canada and select export markets (per the firm's website).
Does Odan Laboratories engage in external investments or fund commitments?
Odan does not publicly disclose any external fund investments or direct capital allocation beyond operating its pharmaceutical business. Its known financial activities are limited to operational reinvestment and the acquisition of other pharma companies (per the firm's website).
How does Odan's acquisition strategy work?
Odan acquires complementary pharmaceutical companies to expand its product portfolio and market reach. Its most recent disclosed acquisition is Ilkos Therapeutic Inc. (per the firm's website, 2026). No financial terms or deal rationale were published.
What is the source of Odan's wealth?
The source of Odan's capital is not publicly disclosed. The company does not reveal whether it is funded by a single family, a group of investors, or retained earnings from its pharmaceutical operations.
Is Odan Laboratories a family office or an operating company?
Odan presents itself exclusively as an operating pharmaceutical company. There is no public indication that it functions as a family office with an external investment mandate. Its activities are fully focused on pharmaceutical R&D, manufacturing, and distribution.
Which regions does Odan serve?
Odan distributes primarily across Canada and exports to several other countries internationally. Specific export markets are not listed (per the firm's website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: